Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Prof. Éric Vivier Receives the 2026 William B. Coley Award
The Cancer Research Institute (CRI) has awarded the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology to Prof. Éric Vivier, holder of the Natural Killer (NK) Cell Chair of the Fondation Gustave Roussy. This distinction, one of the most prestigious in cancer immunology, recognizes his body of work, which has profoundly transformed the understanding of antitumor immunity and paved the way for new therapeutic approaches.
Published on
The Cancer Research Institute (CRI) has awarded the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology to Prof. Éric Vivier, holder of the Natural Killer (NK) Cell Chair of the Fondation Gustave Roussy. This distinction, one of the most prestigious in cancer immunology, recognizes his body of work, which has profoundly transformed the understanding of antitumor immunity and paved the way for new therapeutic approaches.
The William B. Coley Award honors researchers whose discoveries have had a lasting impact on the field of cancer immunology. The award will be presented to Prof. Éric Vivier on October 20, 2026, in New York. He will also deliver the Coley Lecture during the annual Society for Immunotherapy of Cancer (SITC) conference on November 8, 2026, in Phoenix, Arizona.
Professor of Immunology at Aix Marseille Université, hospital practitioner at Assistance Publique–Hôpitaux de Marseille (AP-HM), co-founder of the Marseille-Luminy Center of Immunology, and President of the Paris-Saclay Cancer Cluster (PSCC), Prof. Éric Vivier is one of the pioneers in the study of NK cells. For more than thirty years, his research has contributed to a better understanding of the essential role these cells play in recognizing and eliminating cancer cells.
At Gustave Roussy, Prof. Éric Vivier leads the Fondation Gustave Roussy Natural Killer (NK) Cell Chair, which explores the therapeutic potential of these cells in order to enhance their antitumor activity and develop new strategies aimed at strengthening the immune response against cancer.
NK Cells at the Heart of Immunotherapy
NK cells are white blood cells involved in innate immunity that can rapidly detect and eliminate cancer cells while sparing healthy cells. They also play a key role in activating other components of the immune response, particularly macrophages and T lymphocytes.
They have helped establish innate immunity as a cornerstone of modern immunotherapy and are now driving the development of new therapeutic approaches currently being evaluated in clinical trials.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
